Lymphoplasmacytic Lymphoma

To our knowledge, this is the first RWE study of WM patients in Finland.

This international study evaluated 253 patients receiving frontline fixed-duration bendamustine-rituximab (BR), a common chemoimmunotherapy for WM. In conclusion, BR is effective, irrespective of the MYD88 status, but CXCR4 mutations and POD24 portend worse outcomes. Non-POD24 patients represent a cohort with distinctly favorable outcome.

P1/2, N=53, Active, not recruiting, Fred Hutchinson Cancer Center | Trial completion date: Nov 2037 --> Mar 2039

P=N/A, N=212, Active, not recruiting, Fondazione Italiana Linfomi - ETS | Recruiting --> Active, not recruiting | N=125 --> 212

As non-IgM LPL cases have historically been associated with poorer prognoses compared to Waldenström macroglobulinemia, the identification of underlying kidney complications such as LCDD is essential. Further accumulation of similar cases is needed to establish optimal treatment strategies.

P1, N=27, Active, not recruiting, City of Hope Medical Center | Trial completion date: Nov 2025 --> Nov 2026 | Trial primary completion date: Nov 2025 --> Nov 2026

The therapeutic options for WM patients include a combination of Rituximab (anti-CD20 monoclonal antibody) and chemotherapy, with newer treatments like proteasomal inhibitors and Bruton's Tyrosine Kinase (BTK) inhibitors showing high levels of success both as monotherapy and in combinations...In this review, we aim to provide a comprehensive summary of WM, focusing on the genetic mutations and signalling pathways driving disease progression. In addition, we highlight the current therapeutics and emerging clinical trials to provide novel insights to drive deep and durable responses.

The patient was treated with bendamustine-based chemotherapy and corticosteroids, with marked clinical and radiological improvement. This case emphasizes the importance of considering hematologic malignancies in the differential diagnosis of breast lesions to avoid unnecessary surgical management and ensure appropriate systemic therapy.

The patient was treated with a bortezomib-based regimen including bortezomib, lenalidomide, and dexamethasone, along with supportive therapy including bisphosphonates and thromboprophylaxis. This case highlights the diagnostic complexity of IgM MM and emphasizes the importance of comprehensive evaluation, including bone marrow examination, advanced imaging, and detailed protein studies for accurate differentiation from other IgM-producing disorders. Early recognition and appropriate treatment with novel agents may improve outcomes in this rare myeloma variant.

P2, N=90, Active, not recruiting, BeiGene | Trial completion date: Oct 2025 --> Dec 2025 | Trial primary completion date: Oct 2025 --> Dec 2025

Post Bruton's tyrosine kinase inhibitors, novel therapies and combinations are being investigated. Ongoing work on issues of quality of life and patient reported outcomes will better inform our understanding of patient experience and should be reported in clinical trials.

P1/2, N=161, Completed, Acerta Pharma BV | Active, not recruiting --> Completed | Trial completion date: Apr 2026 --> Oct 2025